A Complete Response to Immune Checkpoint Therapy in A Treatment Refractory Patient with Metastatic Pancreatic Cancer and Mismatch Repair Deficiency

Nicholas Jette^1*, Adam Fundytus² and Jose Monson³

¹Cumming School of Medicine, University of Calgary, Calgary, Canada

²Division of Cancer Care and Epidemiology, Queen's University, Canada

³Medical Oncologist, Tom Baker Cancer Centre, Canada

*Corresponding Author:
Nicholas Jette
Cumming School of Medicine
University of Calgary, Calgary, Canada
E-mail: nrjette@ucalgary.ca

Received: December 01, 2020 Accepted: December 15, 2020 Published: December 22, 2020

Citation: Jette N, Fundytus A, J Monson J (2020) A Complete Response to Immune Checkpoint Therapy in a Treatment Refractory Patient with Metastatic Pancreatic Cancer and Mismatch Repair Deficiency. Clin Oncol Case Rep 4:1

Abstract

Pancreatic cancer remains a difficult to treat malignancy. Advanced application of targeted chemotherapeutics has extended survival but has not resulted in cure. Recently, the application of immunotherapy has shown promise in cancers that harbour mismatch repair deficiencies and micro-satellite instability. Here, we show a metastatic pancreatic cancer with a mismatch repair deficiency respond dramatically to PD-1 inhibitor therapy.